Xiaoran Han
Impact in
- Oncology top 5%
- Peptidase Inhibition and Analysis
- Lung Cancer Research Studies
-
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
Papers in
-
- Ubiquitin and proteasome pathways 7
- Protein Degradation and Inhibitors 7
- Receptor Mechanisms and Signaling 2
- Oncology 5
- PARP inhibition in cancer therapy 2
- Co-authors
- Chen Mao (1 shared paper)Zu‐Yao Yang (1 shared paper)Jin-Ling Tang (1 shared paper)Diane Threapleton (1 shared paper)Jin-Qiu Yuan (1 shared paper)Xiaohong Fu (1 shared paper)Yuelun Zhang (1 shared paper)Kaifeng Wang (1 shared paper)
- Journals
- Journal of Medicinal Chemistry (3 papers)Molecular Cell (1 paper)Pharmaceutics (1 paper)ChemCatChem (1 paper)Cephalalgia (1 paper)
- Partner nations
- ChinaUnited StatesHong Kong
In The Last Decade
Xiaoran Han
19 papers receiving 1.2k citations
Xiaoran Han's Hit Papers
Peers
Comparison fields: 5 of 71
- Oncology 458
- Pulmonary and Respiratory Medicine 470
- Hematology 166
- Molecular Biology 652
- Cancer Research 115
Countries citing papers authored by Xiaoran Han
This map shows the geographic impact of Xiaoran Han's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaoran Han with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaoran Han more than expected).
Fields of papers citing papers by Xiaoran Han
This network shows the impact of papers produced by Xiaoran Han. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaoran Han. The network helps show where Xiaoran Han may publish in the future.
Co-authors
The 25 scholars most cited alongside Xiaoran Han, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 21 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis Hit paper breakdown → | 2016 | 557 |
| 2 | 2018 | 187 | |
| 3 | 2020 | 148 | |
| 4 | 2022 | 93 | |
| 5 | 2020 | 50 | |
| 6 | 2020 | 39 | |
| 7 | 2020 | 32 | |
| 8 | 2015 | 29 | |
| 9 | 2019 | 24 | |
| 10 | 2022 | 13 | |
| 11 | 2016 | 13 | |
| 12 | 2024 | 8 | |
| 13 | 2024 | 5 | |
| 14 | 2024 | 2 | |
| 15 | 2025 | 2 | |
| 16 | 2025 | 2 | |
| 17 | 2025 | 2 | |
| 18 | 2020 | 1 | |
| 19 | 2025 | 1 | |
| 20 | 2025 | 0 |
About Xiaoran Han
Xiaoran Han is a scholar working on Molecular Biology, Oncology, Surgery, Pulmonary and Respiratory Medicine and Hematology, having authored 21 papers that have together received 1.2k indexed citations. Recurring topics across this work include Ubiquitin and proteasome pathways (7 papers), Protein Degradation and Inhibitors (7 papers), Multiple Myeloma Research and Treatments (3 papers), Fuel Cells and Related Materials (2 papers), Receptor Mechanisms and Signaling (2 papers), PARP inhibition in cancer therapy (2 papers), Advanced Drug Delivery Systems (2 papers) and Advanced battery technologies research (2 papers). The work is most often cited by research in Oncology (458 citations), Pulmonary and Respiratory Medicine (470 citations), Hematology (166 citations), Molecular Biology (652 citations) and Cancer Research (115 citations). Xiaoran Han has collaborated with scholars based in China, United States and Hong Kong. Frequent co-authors include Chen Mao, Zu‐Yao Yang, Jin-Ling Tang, Diane Threapleton, Jin-Qiu Yuan, Xiaohong Fu, Yuelun Zhang, Kaifeng Wang, Yue Xiong and Jian Jin. Their work appears in journals such as Journal of Medicinal Chemistry, Molecular Cell, Pharmaceutics, ChemCatChem and Cephalalgia.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.